Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 157 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Iomab-B for active, relapsed or refractory acute myeloid leukaemia in older patients (aged 55 years and older)	I-131-Apamistamab (Iomab-B)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Imetelstat for treating relapsed or refractory intermediate-2 or high-risk myelofibrosis after janus kinase inhibitor treatment	Imlunestrant	Myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2024	View \| Download
Imetelstat for Myelodysplastic syndrome	Imetelstat (GRN163L; JNJ-63935937)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2020	View \| Download
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 therapies	Idecabtagene vicleucel (Ide-cel; bb2121)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Idasanutlin in addition to cytarabine for relapsed or refractory acute myeloid leukaemia	Cytarabine , Idasanutlin (RG7388; RO5503781)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2019	View \| Download
Ibrutinib with Venetoclax and Obinutuzumab for the treatment of Chronic Lymphocytic Leukaemia patients with TP53 deletion and/or mutation	Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Ibrutinib in combination with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma – first line	Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2020	View \| Download